Search

Sarepta Therapeutics Inc

Geschlossen

BrancheGesundheitswesen

19.97 -3.39

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

19.59

Max

20.11

Schlüsselkennzahlen

By Trading Economics

Einkommen

-4.9M

326M

Verkäufe

-330M

401M

KGV

Branchendurchschnitt

42.919

56.432

EPS

0.42

Gewinnspanne

81.263

Angestellte

835

EBITDA

-345M

30M

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

+10.82% upside

Dividenden

By Acuity

Nächstes Ergebnis

2. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

533M

2.2B

Vorheriger Eröffnungskurs

23.36

Vorheriger Schlusskurs

19.97

Nachrichtenstimmung

By Acuity

40%

60%

70 / 339 Ranking in Healthcare

Sarepta Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

18. Sept. 2026, 19:51 UTC

Sarepta Therapeutics Inc shares fell sharply, continuing a significant decline since Thursday and trading well below its 20-day moving average.

17. Sept. 2026, 20:02 UTC

Sarepta Therapeutics Inc shares are sharply higher, showing notable volatility and remaining well above the 20-day moving average since Wednesday's close.

16. Sept. 2026, 23:06 UTC

Sarepta Therapeutics Inc. is trading modestly higher in after-market hours following a notable early spike, despite closing lower in three consecutive sessions.

14. Sept. 2026, 20:07 UTC

Sarepta Therapeutics shares are higher, reflecting broader market strength despite pulling back from an earlier session peak. No specific news was identified for the movement.

12. Sept. 2026, 00:01 UTC

Sarepta Therapeutics Inc shares are lower in after-market trading, following a decline earlier in the session amid broader inflation concerns ahead of a Federal Reserve meeting.

11. Sept. 2026, 23:31 UTC

Sarepta Therapeutics Inc shares are lower in after-market hours with no specific news to explain the decline amid broader market speculation on Federal Reserve rate hikes.

10. Sept. 2026, 20:03 UTC

Sarepta Therapeutics Inc shares are lower today, continuing a decline since Wednesday. No specific news was identified to explain the drop.

9. Sept. 2026, 23:21 UTC

Sarepta Therapeutics shares are lower in after-market hours, following a broader market trend amid rising U.S. Treasury yields impacting borrowing costs.

8. Sept. 2026, 23:21 UTC

Social Media

Sarepta Therapeutics is higher in after-market trading amid social media interest in its $2.1 billion market cap and revenue projections for fiscal year 2026.

4. Sept. 2026, 23:25 UTC

Sarepta Therapeutics Inc. shares declined after-market, reflecting unusual weakness since Friday's close, despite remaining above the 20-day moving average.

3. Sept. 2026, 23:36 UTC

Sarepta Therapeutics Inc. shares traded roughly flat after market hours, while major indices gained amid easing interest rate concerns.

2. Sept. 2026, 20:02 UTC

Social Media

Sarepta Therapeutics shares are higher as investor interest grows ahead of clinical data for treatments targeting muscular dystrophy, despite a pullback from session highs.

1. Sept. 2026, 20:09 UTC

Sarepta Therapeutics Inc shares are higher today, supported by gains in the Biotechnology sub-sector. The stock remains above its 20-day moving average.

31. Aug. 2026, 20:07 UTC

Sarepta Therapeutics shares are higher amid broader market concerns over inflation, with no specific company news identified to explain the movement.

28. Aug. 2026, 19:51 UTC

News

Sarepta Therapeutics reported a 34% revenue decline to $401.3 million for Q2 2026, as execution risks weigh on shares during the current session.

27. Aug. 2026, 23:02 UTC

Sarepta Therapeutics shares declined in after-market trading amid a broader market pullback, despite earlier gains during the session. No specific news was identified.

26. Aug. 2026, 20:08 UTC

Sarepta Therapeutics Inc shares are higher today amid broader market gains, despite no specific company news identified. Recent inflation data may be influencing market trends.

25. Aug. 2026, 19:26 UTC

Sarepta Therapeutics Inc. shares are higher today amid notable volatility, despite no specific news to explain the movement. Broader market conditions support higher valuations.

24. Aug. 2026, 20:06 UTC

News

Sarepta Therapeutics shares decline amid investigation into potential fiduciary breaches and safety concerns regarding its gene therapy, Elevidys.

21. Aug. 2026, 19:26 UTC

Sarepta Therapeutics Inc is trading lower today, with no specific news identified for the decline. Broader market trends show a rebound in U.S. stocks.

20. Aug. 2026, 23:56 UTC

Sarepta Therapeutics Inc. shares traded roughly flat in after-market hours, remaining above their 20-day moving average and near the upper end of their one-month range.

19. Aug. 2026, 23:11 UTC

Sarepta Therapeutics shares are lower in after-market hours amid a broader decline in the Biotechnology sub-sector, showing unusual volatility during the session.

18. Aug. 2026, 23:11 UTC

Sarepta Therapeutics Inc shares are lower in after-market hours, retracing gains amid broader market weakness linked to rising sovereign bond yields and inflation concerns.

17. Aug. 2026, 19:36 UTC

Sarepta Therapeutics Inc shares are higher, continuing their advance since Friday's close and trading above the 20-day moving average. No specific news was identified.

14. Aug. 2026, 19:36 UTC

Sarepta Therapeutics shares are lower today amid broader market sentiment following a reported decline in retail sales for July. No specific company news was identified.

13. Aug. 2026, 19:36 UTC

Sarepta Therapeutics shares are trading roughly flat, with no specific news identified. The price remains significantly above the 20-day moving average.

12. Aug. 2026, 23:51 UTC

Sarepta Therapeutics Inc shares are lower in after-market hours, continuing a decline since Wednesday's close, with no specific news identified to explain the drop.

11. Aug. 2026, 23:51 UTC

Sarepta Therapeutics Inc shares are lower in after-market trading. No specific news was identified to explain the movement amid broader market focus on inflation data.

10. Aug. 2026, 23:52 UTC

Sarepta Therapeutics shares are lower in after-market hours, with no specific news identified for the decline amid broader market sentiment influenced by labor report data.

7. Aug. 2026, 19:36 UTC

News

Sarepta Therapeutics reports Q2 2026 revenue of $401.3 million, down from $611.1 million a year earlier, with shares trading lower during the session.

Peer-Vergleich

Kursveränderung

Sarepta Therapeutics Inc Prognose

Kursziel

By TipRanks

10.82% Vorteil

12-Monats-Prognose

Durchschnitt 22.286 USD  10.82%

Hoch 38 USD

Tief 5 USD

Basierend auf 16 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Sarepta Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

16 ratings

4

Buy

8

Halten

4

Sell

Stimmung

By Acuity

70 / 339 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Durchschnitt

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.